Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 25, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for February 18, 2005 Subscribe to this News Feed     Subscribe to this Podcast Feed  
 

Beasley Allen Calls Upon Merck to Leave Vioxx Off the Market

Experienced lawsuit attorneys have been reviewing patient cases against Merck since 2000. They urge Merck to honor the September 2004 Vioxx recall

Montgomery, AL (PRWEB) February 18, 2005 -- Andy Birchfield, lead Vioxx Attorney at Beasley Allen Law Firm, has called upon Merck to do the right thing and leave Vioxx off the market.

An FDA advisory panel voted today (17-16) that Vioxx could be placed back on the market. Merck officials have recently stated that they would consider re-introducing the controversial painkiller to the market based on the FDA panel findings.

Beasley Allen has been watching the situation unfold over the past 4 years. We feel that Merck finally did the right thing in September by withdrawing Vioxx from the market, and to reintroduce the drug now would most certainly result in further cardiovascular injuries, including death. The fact that Merck is even considering putting the pain medication back on the market clearly shows their motives to put profits above people.

When Merck & Co. pulled Vioxx from the market in September, it said it was acting because a clinical trial had shown that users were at increased risk of heart attacks or strokes. Until it pulled the drug last September, Merck defended the painkiller as safe.

Several studies have shown a direct link between Vioxx and increased cardiovascular risk. According to an internal study conducted by FDA scientist Dr. David Graham, up to 140,000 people may have suffered heart attacks as a direct result of taking the pain medication. And millions of people may have been exposed unnecessarily to the risk of heart attack by taking Cox-2 inhibitor drugs, including Vioxx.

Todays advisory panel vote on Vioxx illustrates the weakness of the current drug control policy and reinforces the need for immediate FDA reform.

For more information:
Andy Birchfield, Attorney
Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.
1-800-898-2034 toll free
1-334-954-7555 fax
andy.birchfield@beasleyallen.com

Online Media Contact:
Jayme Yarroch
1-800-898-2343 toll free
1-334-657-8959 mobile
jayme.yarroch@beasleyallen.com
Beasley Allen Law Firm
Vioxx Lawsuit Information

###

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Jayme Yarroch
Beasley Allen Law Firm
1-800-898-2343
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright